Agios Pharmaceuticals, Inc. (FRA:8AP)

Agios Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-412.78	673.73	-352.09	-231.8	1,605
Depreciation & Amortization	5.18	5.65	6.62	8.56	9.24
Loss (Gain) From Sale of Assets	0.01	-200.04	0.55	-0.05	0.01
Loss (Gain) From Sale of Investments	-7.31	-14.65	-5.08	-1.2	6.95
Stock-Based Compensation	52.55	42.85	44.77	49.3	53.51
Other Operating Activities	22.43	-877.61	28.22	-117.86	-1,952
Change in Accounts Receivable	-6.47	-1.3	-0.6	-2.21	-
Change in Inventory	-5.3	-8.54	-10.58	-8.49	-
Change in Accounts Payable	1.75	6.6	-8.73	3.44	1.86
Change in Income Taxes	-0.87	0.87	-	-	-
Change in Other Net Operating Assets	-22.15	-17.4	0.86	-9.17	-38.69
Operating Cash Flow	-372.98	-389.84	-296.06	-309.48	-407.32
Capital Expenditures	-4.32	-1.69	-1	-4.88	-5.74
Sale of Property, Plant & Equipment	-	0.04	1.33	0.96	-
Divestitures	-	200	-	-	-
Sale (Purchase) of Intangibles	-10	-	-17.5	-	-
Investment in Securities	391.5	-724.05	256.75	115.39	-548.42
Other Investing Activities	-	889.14	-	131.78	1,803
Investing Cash Flow	377.18	363.44	239.58	243.26	1,249
Long-Term Debt Repaid	-	-	-	-0.33	-0.58
Net Debt Issued (Repaid)	-	-	-	-0.33	-0.58
Issuance of Common Stock	8.68	14.44	5.43	2.68	37.3
Repurchase of Common Stock	-	-	-	-	-802.49
Financing Cash Flow	8.68	14.44	5.43	2.35	-765.77
Net Cash Flow	12.88	-11.96	-51.05	-63.87	75.69
Free Cash Flow	-377.29	-391.53	-297.06	-314.36	-413.06
Free Cash Flow Margin	-698.33%	-1072.73%	-1107.49%	-2207.58%	-
Free Cash Flow Per Share	-6.51	-6.76	-5.34	-5.74	-6.83
Cash Income Tax Paid	0.63	43.15	1.57	-	16.08
Levered Free Cash Flow	-267.97	-222.83	-215.06	-195.32	-198.29
Unlevered Free Cash Flow	-267.97	-222.83	-215.06	-195.32	-198.29
Change in Working Capital	-33.04	-19.77	-19.06	-16.43	-36.82

Source: S&P Global Market Intelligence. Standard template. Financial Sources.